We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Global drug spending will climb to $1.5 trillion in the next five years, marking a nearly 32 percent increase, fueled largely by new medicines and emerging markets. Read More
Six generics makers are facing a civil lawsuit for allegedly colluding to fix the prices of the antibiotic doxycycline hyclate and the diabetes drug glyburide. Read More
UK’s antitrust agency has accused Actavis of breaching competition law by raising the price of generic hydrocortisone tablets for Addison’s disease by more than 12,000 percent since 2008. Read More
Juno has filed a lawsuit against Kite Pharma for the alleged infringement of eight patent claims covering a cancer immunotherapy that uses a chimeric T cell receptor. Read More
Teva alleges six generics makers infringed a patent covering its multiple sclerosis therapy Copaxone when seeking approvals for copycat versions of the drug. Read More
A majority of patent settlements reached last year in the European Union restricted the market entry of generics, according to a European Commission report. Read More
The U.S. Supreme Court has declined to hear a case on whether all biosimilar makers must give a six-month notice before bringing an FDA-approved product to market, even when disclosures were made earlier in the approval process. Read More
The U.S. solicitor general has urged the Supreme Court to review a Federal Circuit decision that requires some biosimilar makers wait six months after receiving FDA approval to launch a product. Read More
Gilead will have to pay Merck $2.5 billion for infringing a patent that covers the active ingredient of its blockbuster hepatitis C drugs, Salvadi and Harvoni, in the country’s largest ever judgment for an infringement. Read More
Spanish drugmaker Grifols is accused of defrauding the government of millions of dollars for promoting the use of its antithrombin drug, Thrombate III, in unapproved indications. Read More
Eli Lilly & Co. had their patent sustained by a federal appeals court, barring generics manufacturer Teva Pharmaceuticals from marketing its own version of the billion-dollar cancer drug Alimta. Read More